G. Goyette

This study identifies two potent neutralizing antibodies, EH3 and EH8, from a pediatric patient that cross-neutralize SARS-CoV-2 variants and provide in vivo protection against the Delta VOC.

This study identifies HIV-1 Env variants resistant to CD4-mimetic compounds and BMS-806 by analyzing mutations that confer resistance and their effects on viral fitness and inhibitor sensitivity.

The paper identifies a highly divergent SARS-CoV-2 lineage in white-tailed deer with evidence of deer-to-human transmission.

This study shows that HIV-1 Vpu reduces nnAb recognition and ADCC resistance, with nnAb Fc-effector functions dependent on Env's open conformation.

VE607 inhibits SARS-CoV-2 infection by stabilizing the RBD in the 'up' conformation and blocking S-ACE2 interaction across multiple variants.

This study evaluates how plasma from individuals with a 16-week interval between BNT162b2 mRNA vaccine doses recognizes and neutralizes the Omicron Spike compared to other variants.

The paper examines B and T cell immunity responses to a 16-week interval BNT162b2 vaccine regimen, finding robust immune memory and functional associations between immune components.

This study evaluates mRNA vaccine immunogenicity in HIV-positive individuals, finding similar anti-RBD IgG responses to controls in those with CD4 counts >250 cells/mm3, but significantly lower responses in those with <250 cells/mm3.

The paper evaluates how single mutations in SARS-CoV-2 Spike protein affect antigenicity and ACE2 binding in emerging variants.

This study characterizes two SARS-CoV-2 antibodies effective against variants, showing their structural basis and mechanisms of neutralization.

This study investigates how temperature affects SARS-CoV-2 Spike protein affinity for ACE2, finding increased binding at low temperatures, which is mitigated by the N501Y mutation.

This study uses live imaging to show that neutralizing antibodies against SARS-CoV-2 need both Fab and Fc functions to effectively prevent and resolve infection in mice.

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

This study tracks humoral immune responses in convalescent individuals up to 8 months post-SARS-CoV-2 infection, showing that IgG+ memory B cells persist while plasma antibody levels decline.

This study evaluates humoral responses against SARS-CoV-2 Spike in 106 infected individuals, finding persistent RBD-specific IgG and declining neutralizing activity over time.